Cosette M Wheeler Selected Research

Infections

1/2022	Immunogenicity and Protective Capacity of a Virus-like Particle Vaccine against Chlamydia trachomatis Type 3 Secretion System Tip Protein, CT584.
1/2021	Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study.
1/2020	Antibodies to Variable Domain 4 Linear Epitopes of the Chlamydia trachomatis Major Outer Membrane Protein Are Not Associated with Chlamydia Resolution or Reinfection in Women.
10/2016	Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
1/2016	Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico.
7/2015	Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.
4/2015	Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
2/2015	Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.
10/2014	Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial.
8/2014	Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cosette M Wheeler Research Topics

Disease

28	Infections 01/2022 - 10/2002
28	Uterine Cervical Dysplasia 01/2021 - 11/2002
24	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2020 - 01/2003
20	Neoplasms (Cancer) 01/2022 - 01/2003
18	Papillomavirus Infections 01/2021 - 07/2004
9	Atypical Squamous Cells of the Cervix 12/2016 - 03/2002
8	Squamous Intraepithelial Lesions 12/2016 - 03/2002
7	Persistent Infection 10/2016 - 05/2005
5	Papilloma (Papillomatosis) 01/2020 - 01/2012
5	Adenocarcinoma in Situ 01/2012 - 05/2007
3	Genital Diseases 03/2010 - 05/2005
3	Condylomata Acuminata (Genital Wart) 03/2010 - 05/2005
2	Carcinoma (Carcinomatosis) 01/2022 - 06/2003
2	Reinfection 01/2020 - 10/2009
2	Warts (Wart) 01/2018 - 07/2010
2	Carcinogenesis 11/2015 - 06/2005
2	Coinfection 01/2012 - 02/2009
1	Prostatic Neoplasms (Prostate Cancer) 10/2017
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2016
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2015
1	Vulvar Diseases 10/2009
1	Hepatitis B 01/2008
1	Injection Site Reaction 07/2004
1	Herpes Simplex 01/2003

Drug/Important Bio-Agent (IBA)

37	VaccinesIBA 01/2022 - 11/2002
22	DNA (Deoxyribonucleic Acid)IBA 11/2015 - 03/2002
12	Papillomavirus Vaccines (HPV Vaccines)IBA 01/2018 - 04/2007
4	Virus-Like Particle VaccinesIBA 12/2011 - 06/2007
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2012
3	AntibodiesIBA 01/2020 - 10/2009
2	EpitopesIBA 01/2022 - 01/2020
2	EnzymesIBA 02/2015 - 06/2003
2	Combined VaccinesIBA 07/2010 - 05/2005
2	Oral ContraceptivesIBA 02/2010 - 12/2005
2	SolutionsIBA 08/2008 - 03/2002
2	HLA Antigens (Human Leukocyte Antigens)IBA 10/2005 - 08/2004
1	Formaldehyde (Formol)FDA Link 01/2022
1	Oncogene Proteins (Oncogene Protein)IBA 01/2021
1	Immunodominant EpitopesIBA 01/2020
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2020
1	Long Noncoding RNAIBA 10/2017
1	P-2 (P 2)IBA 12/2016
1	Hormones (Hormone)IBA 10/2014
1	CarcinogensIBA 06/2014
1	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 01/2014
1	Adenosine Triphosphate (ATP)IBA 01/2012
1	ParaffinIBA 04/2009
1	Proteins (Proteins, Gene)FDA Link 02/2008
1	Histocompatibility Antigens Class IIBA 02/2008
1	tapasinIBA 02/2008
1	Biological ProductsIBA 06/2007
1	Complement System Proteins (Complement)IBA 01/2007
1	Contraceptive Agents (Contraceptives)IBA 12/2005
1	NucleotidesIBA 07/2005
1	CI 22IBA 07/2005
1	Immunoglobulin G (IgG)IBA 06/2005
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2005
1	A-Form DNA (A-DNA)IBA 01/2005
1	HLA-DRB1 Chains (HLA DRB1)IBA 08/2004
1	Indicators and Reagents (Reagents)IBA 10/2002

Therapy/Procedure

2	Microspheres (Microsphere) 02/2008 - 03/2005
1	Hormonal Contraception 01/2016
1	Condoms (Condom) 01/2016
1	Therapeutics 03/2010
1	Secondary Prevention 11/2009
1	Aftercare (After-Treatment) 05/2007
1	Injections 12/2005